A randomized phase II design with a time-to-event endpoint using predictive probability of success of the follow-up phase III study as the criteria for go/no-go decision.

被引：0
|
作者：
Chen, B.
Fan, X.
Wang, Y.
Jauffret, S.
Dey, J.
Waltzman, R.
Lopez-Martin, E. M.
Malek, K.
Kreitz, S.
Zuber, E.
机构：
[1] Novartis Pharmaceut, E Hanover, NJ USA
[2] Novartis Pharma AG, Basel, Switzerland
[3] Novartis Farmaceut SA, Barcelona, Spain
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
10.1200/jco.2010.28.15_suppl.e18078
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e18078
引用
收藏
页数：1
相关论文
共 7 条
  • [1] Optimal Sample Sizes and Go/No-Go Decisions for Phase II/III Development Programs Based on Probability of Success
    Jiang, Kaihong
    [J]. STATISTICS IN BIOPHARMACEUTICAL RESEARCH, 2011, 3 (03): : 463 - 475
  • [2] Quantitative decision-making in randomized Phase II studies with a time-to-event endpoint
    Huang, Bo
    Talukder, Enayet
    Han, Lixin
    Kuan, Pei-Fen
    [J]. JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2019, 29 (01) : 189 - 202
  • [3] Extended follow-up of a phase II trial in relapsed, refractory multiple myeloma - Final time-to-event results from the SUMMIT trial
    Richardson, PG
    Barlogie, B
    Berenson, J
    Singhal, S
    Jagannath, S
    Irwin, DH
    Rajkumar, SV
    Srkalovic, G
    Alsina, M
    Anderson, KC
    [J]. CANCER, 2006, 106 (06) : 1316 - 1319
  • [4] Up to 15-year clinical follow-up of a pilot Phase III immunotherapy study in stage II breast cancer patients using oxidized mannan-MUC1
    Vassilaros, Stamatis
    Tsibanis, Anastasios
    Tsikkinis, Annivas
    Pietersz, Geoffrey A.
    McKenzie, Ian F. C.
    Apostolopoulos, Vasso
    [J]. IMMUNOTHERAPY, 2013, 5 (11) : 1177 - 1182
  • [5] Establishment and validation of a nomogram for predicting the benefit of concurrent chemotherapy in stage II nasopharyngeal carcinoma: A study based on a phase III randomized clinical trial with 10-year follow-up
    Sun, Xue-Song
    Li, Xiao-Yun
    Xiao, Bei-Bei
    Liu, Sai-Lan
    Chen, Qiu-Yan
    Tang, Lin-Quan
    Mai, Hai-Qiang
    [J]. ORAL ONCOLOGY, 2020, 100
  • [6] A phase II, double-blind, randomized, placebo-controlled, dose comparative study of the efficacy, tolerability, and safety of MCC-135 in subjects with chronic heart failure, NYHA class II/III (MCC-135-GO1 study): Rationale and design
    Zile, M
    Gaasch, W
    Little, W
    Francis, G
    Tavazzi, L
    Cleland, J
    Davies, M
    [J]. JOURNAL OF CARDIAC FAILURE, 2004, 10 (03) : 193 - 199
  • [7] Final five year median follow-up data from a prospective, randomized, placebo-controlled, single-blinded, multicenter, phase IIb study evaluating a time series of immune responses using HER2/neu peptide GP2+GM-CSF vs. GM-CSF alone after adjuvant trastuzumab in HER2 positive women with operable breast cancer.
    Patel, Snehal S.
    McWilliams, David B.
    Patel, Mira S.
    Fischette, Christine T.
    Thompson, Jaye
    Daugherty, F. Joseph
    [J]. CANCER RESEARCH, 2021, 81 (13)
1